SH-110

SH-110 is an **oral liquid suspension formulation** being developed by Shorla Oncology for the treatment of **glioma**, a rare form of brain cancer. The drug addresses a critical unmet need for patients with **dysphagia** (difficulty swallowing), who previously had to break open capsules or rely on specialized compounding pharmacies to take their medication. This proprietary liquid formulation offers a safer and more convenient alternative to traditional capsule-based therapies. The drug received **FDA orphan drug designation** in July 2025 for the treatment of glioma. SH-110 is part of Shorla Oncology's portfolio of patient-friendly cancer therapies designed to improve both safety and usability. The drug is expected to launch in Q2 2026. Approximately 13,000 adults and 2,000 children are diagnosed with glioma annually in the United States. The mechanism of action is currently undefined, suggesting SH-110 is a liquid formulation of an existing oncology agent.